GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Improves Glycemic Control as Measured by CGM in Patients with Type 2 Diabetes

被引：0
|
作者：
Nimgaonkar, Ashish
Bryant, Christine
Fineman, Mark
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-875-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
875-P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Reduces Glucose and Bodyweight in Patients with Type 2 Diabetes
    Fineman, Mark
    Colbert, Kevin
    Petersen, John S.
    Jozefiak, Thomas H.
    Nimgaonkar, Ashish
    Bryant, Christine
    DIABETES, 2024, 73
  • [2] GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Decreases Appetite, Increases Satiation, and Reduces Food Intake in Patients with Type 2 Diabetes
    Bryant, Christine
    Nimgaonkar, Ashish
    Fineman, Mark
    DIABETES, 2024, 73
  • [3] GLY-200 (Oral Pharmacologic Duodenal Exclusion) Reduces Bodyweight and Glucose in Patients with T2D
    Bryant, Christine
    Colbert, Kevin
    Petersen, John
    Jozefiak, Thomas
    Nimgaonkar, Ashish
    Fineman, Mark
    OBESITY, 2023, 31 : 39 - 39
  • [4] GLY-200 (Oral Duodenal Exclusion Drug) plus /-Semaglutide Improves Metabolic Parameters in DIO Mice
    Nimgaonkar, Ashish
    Carlson, Taylor
    Kernodle, Stace
    Hutch, Chelsea
    Bryant, Christine
    Colbert, Kevin
    Polomoscanik, Steve
    Petersen, John
    Jozefiak, Thomas
    Seeley, Randy
    Fineman, Mark
    OBESITY, 2024, 32 : 142 - 142
  • [5] GLY-200 (Oral Pharmacologic Duodenal Exclusion) Reduces Appetite and Food Intake in Patients with T2D
    Bryant, Christine
    Nimgaonkar, Ashish
    Fineman, Mark
    OBESITY, 2023, 31 : 178 - 178
  • [6] GLY-200, a Pharmacologic Duodenal Exclusion Therapy, Improved Metabolic Parameters in the DIO Rat
    Nimgaonkar, Ashish
    Bryant, Christine
    Habegger, Kirk M.
    Colbert, Kevin
    Carlson, Taylor
    Polomoscanik, Steven
    Petersen, John S.
    Jozefiak, Thomas H.
    Fineman, Mark
    DIABETES, 2023, 72
  • [7] Validation of duodenal targeting by oral pharmacologic duodenal exclusion therapy for treatment of type 2 diabetes
    Carlson, T.
    Nimgaonkar, A.
    Guerina, T.
    Colbert, K.
    Polomoscanik, S.
    Petersen, J.
    Jozefiak, T.
    Fineman, M.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S102 - S102
  • [8] Duodenal Targeting by Oral Pharmacologic Duodenal Exclusion Therapy for Treatment of Type 2 Diabetes (T2D)
    Nimgaonkar, Ashish
    Bryant, Christine
    Carlson, Taylor
    Guerina, Florence V.
    Colbert, Kevin
    Polomoscanik, Steven
    Petersen, John S.
    Jozefiak, Thomas H.
    Fineman, Mark
    DIABETES, 2023, 72
  • [9] Influence of Seasons on glycemic Control as measured with CGM Metrics in People with Type 1 Diabetes
    Groselj-Strele, Andrea
    Elsayed, Hesham
    Cigler, Monika
    Ziko, Haris
    Hochfellner, Daniel A.
    Kopanz, Julia
    Poettler, Tina
    Secco, Katharina
    Simic, Amra
    Trajanoski, Slave
    Mader, Julia K.
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (SUPPL 6) : 219 - 219
  • [10] Orlistat consistently improves glycemic control in patients with type 2 diabetes
    Hollander, PA
    Van Gaal, L
    DIABETES, 2002, 51 : A472 - A472
12345